Phase 3b trial with potassium binder in patients with HF meets primary endpoint
The DIAMOND trial demonstrates a statistically significant outcome with patiromer versus placebo on the primary endpoint. Results suggest that treatment with patiromer is beneficial to control serum potassium levels in HF patients with active hyperkalemia or history of hyperkalemia while treated with RAASi therapy.
Treatment with patiromer enabled 85% of patients to be optimized to guideline-recommended doses of RAASi, including MRA, during the run-in phase of the study. Patiromer was generally well tolerated in the trial population, without unexpected safety findings.
Prof. Javed Butler, principal investigator of the DIAMOND study, stated “The totality of evidence from the trials with patiromer suggests the treatment to control serum potassium and preventing hyperkalemia in heart failure patients aiding longer term optimal medical therapy.”
The DIAMOND trial was a global, multicenter, double-blind, placebo controlled study which evaluated the role of patiromer in enabling HF patients with active hyperkalemia or a history of hyperkalemia to remain on RAASi therapy. The primary endpoint has been changed in June 2021, on recommendation of the independent study Executive Committee and due to COVID-19 impact on recruitment, to investigate the role of patiromer in controlling serum potassium, preventing hyperkalemia and maintain RAASi use in HF patients.
Full data will be presented at a major conference in the first half of 2022.